The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
The Gothenburg Breast Screening Trial
Open accessAbstract
BACKGROUND: Although there is evidence for a reduction in breast carcinoma mortality with mammographic screening, some doubts have been expressed, and there is still uncertainty regarding the age specific effects. METHODS: The authors report on a randomized, controlled trial of mammographic screening for breast carcinoma that was conducted among 51,611 women (21,650 women who were invited to a screening [the study group] and 29,961 women in a control group) ages 39–59 years in Gothenburg, Sweden. Among women in the study group, the screening interval was 18 months. The screening phase of the trial took place in 1982–1991, and follow‐up for breast carcinoma mortality continued until December 31, 1996. Mortality from breast carcinoma was analyzed using a Poisson regression model. Overall and age specific effects of invitation to mammography screening on breast carcinoma mortality were calculated. Three mortality effects were estimated: the effect on deaths from breast tumors diagnosed during the screening phase of the trial, as assessed by an independent Endpoint Committee (the EPC evaluation model); the effect on deaths from breast carcinoma diagnosed during the screening phase of the trial, as determined by data from the National Cancer Registry and the National Cause of Death Register (the SCB evaluation model); and the effect on deaths from all breast carcinomas diagnosed up to December 31, 1996, as determined by the National Cancer Registry and the National Cause of Death Register (the SCB follow‐up model). RESULTS: A nonsignificant, 21% reduction in the rate of mortality from breast carcinoma with invitation to screening was observed using the EPC evaluation model (relative risk [RR], 0.79; 95% confidence interval [95% CI], 0.58–1.08; P = 0.14); and a borderline significant, 23% rate reduction was observed using the SCB follow‐up model (RR, 0.77; 95% CI, 0.60–1.00; P = 0.05). Age specific analyses yielded greater mortality rate reductions for the groups of women ages 39–44 years, 45–49 years, and 55–59 years, but there was no mortality rate reduction in the group of women ages 50–54 years. The effects of invitation to mammographic screening on the incidence of lymph node‐positive disease closely paralleled the effects of invitation on breast carcinoma mortality. The effect on breast carcinoma mortality was consistent with the effect on all‐cause mortality, suggesting no bias in classification of cause of death. Breast carcinoma incidence in the study group was almost identical to the incidence in the control group after trial by screening had ended in the control group (RR, 0.98; 95% CI, 0.88–1.09; P = 0.7). CONCLUSIONS: The current results support the commonly observed 20–30% reduction in breast carcinoma mortality with invitation to screening. The impression that screening is less effective in women younger than 50 years may be an oversimplification. Age specific effects should be a target for further research. Cancer 2003;10:2387–96. © 2003 American Cancer Society. DOI 10.1002/cncr.11361
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies
Juul, S. (1989) · Scandinavian Journal of Social Medicine · doi:10.1177/140349488901700214 · Cited by 3,592
Long-term effects of mammography screening: updated overview of the Swedish randomised trials
Nyström, L., Andersson, I., Bjurstam, N., Frisell, J., Nordenskjöld, B., & Rutqvist, L. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08020-0 · Cited by 1,183
Self-citationBreast cancer screening with mammography: overview of Swedish randomised trials
Nyström, L., Wall, S., Rutqvist, L. E., Lindgren, A., Lindqvist, M., Rydén, S., Andersson, J., Bjurstam, N., Fagerberg, G., Frisell, J., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)91067-v · Cited by 968
Self-citationMammographic screening and mortality from breast cancer: the Malmö mammographic screening trial.
Andersson, I., Aspegren, K., Janzon, L., Landberg, T., Lindholm, K., Linell, F., Ljungberg, O., Ranstam, J., & Sigfússon, B. (1988) · BMJ · doi:10.1136/bmj.297.6654.943 · Cited by 916
Is screening for breast cancer with mammography justifiable?
Gøtzsche, P. C., & Olsen, O. (2000) · The Lancet · doi:10.1016/s0140-6736(99)06065-1 · Cited by 853
Miller, A. B., Baines, C. J., To, T. M., & Wall, C. (1992) · Europe PMC (PubMed Central) · Cited by 744
UPDATE OF THE SWEDISH TWO-COUNTY PROGRAM OF MAMMOGRAPHIC SCREENING FOR BREAST CANCER
Tabàr, L., Fagerberg, G., Duffy, S. W., Day, N. E., Gad, A., & Gröntoft, O. (1992) · Radiologic Clinics of North America · doi:10.1016/s0033-8389(22)02494-0 · Cited by 731
Self-citationCochrane review on screening for breast cancer with mammography
Olsen, O., & Gøtzsche, P. C. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06449-2 · Cited by 710
Efficacy of breast cancer screening by age. New results swedish two-county trial
Tabar, L., Fagerberg, G., Chen, H.-H., Duffy, S. W., Smart, C. R., Gad, A., & Smith, R. A. (1995) · Cancer · doi:10.1002/1097-0142(19950515)75:10<2507::aid-cncr2820751017>3.0.co;2-h · Cited by 557
Self-citationPeriodic Screening for Breast Cancer: The Health Insurance Plan Project and Its Sequelae, 1963-1986
Miller, A. B., Shapiro, S., Venet, W., Strax, P., & Venet, L. (1989) · Journal of Public Health Policy · doi:10.2307/3342801 · Cited by 438
Cited by
Screening for breast cancer with mammography
Gøtzsche, P. C., & Jørgensen, K. J. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001877.pub5 · Cited by 1,869
Screening for Breast Cancer: An Update for the U.S. Preventive Services Task Force
Nelson, H. D., Tyne, K., Naik, A., Bougatsos, C., Chan, B. K., & Humphrey, L. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-10-200911170-00009 · Cited by 1,248
Mortality results from the Göteborg randomised population-based prostate-cancer screening trial
Hugosson, J., Carlsson, S., Aus, G., Bergdahl, S., Khatami, A., Lodding, P., Pihl, C.-G., Stranne, J., Holmberg, E., & Lilja, H. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70146-7 · Cited by 936
American Cancer Society Guidelines for Breast Cancer Screening: Update 2003
Smith, R. A., Saslow, D., Andrews Sawyer, K., Burke, W., Costanza, M. E., Evans, W. P., Foster, R. S., Hendrick, E., Eyre, H. J., & Sener, S. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.3.141 · Cited by 770
Benefits and Harms of Breast Cancer Screening: A Systematic Review
Myers, E. R., Moorman, P., Gierisch, J. M., Havrilesky, L. J., Grimm, L. J., Ghate, S., Davidson, B., Mongtomery, R. C., Crowley, M. J., McCrory, D. C., et al. (2015) · JAMA · doi:10.1001/jama.2015.13183 · Cited by 637
Metadata
- Authors
- Bjurstam, N., Björneld, L., Warwick, J., Sala, E., Duffy, S. W., Nyström, L., Walker, N., Cahlin, E., Eriksson, O., Hafström, L., Lingaas, H., Mattsson, J., Persson, S., Rudenstam, C., Salander, H., Säve‐Söderbergh, J., & Wahlin, T.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2003-04-30
- Volume
- 97
- Issue
- 10
- Pages
- 2387-2396
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1985869352
- Cited by
- 308
- References
- 27
- FWCI
- 6.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Gothenburg Breast Screening Trial. https://app.cochat.ai/papers/10.1002/cncr.11361
- The paper
- Bjurstam, N., Björneld, L., Warwick, J., Sala, E., Duffy, S. W., Nyström, L., Walker, N., Cahlin, E., Eriksson, O., Hafström, L., Lingaas, H., Mattsson, J., Persson, S., Rudenstam, C., Salander, H., Säve‐Söderbergh, J., & Wahlin, T. (2003). The Gothenburg Breast Screening Trial. Cancer. https://doi.org/10.1002/cncr.11361
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.